Publication:
Therapeutic drug monitoring in pediatric patients treated with anti-tuberculosis medications by high performance liquid chromatography

Simple item page
dc.contributor.authorOKUYAN, BETÜL
dc.contributor.authorTOK, FATİH
dc.contributor.authorKARAKUŞ, SEVGİ
dc.contributor.authorKAYMAKÇIOĞLU, BEDİA
dc.contributor.authorSANCAR, MESUT
dc.contributor.authorsOKUYAN B., TOK F., KARAKUŞ S., Dalgiç N., ÇAKIR E., Midyat L., Koçyiğit-Kaymakçioğlu B., Berk U. E. , İZZETTİN F. V. , Rollas S., et al.
dc.date.accessioned2022-12-27T08:39:19Z
dc.date.available2022-12-27T08:39:19Z
dc.date.issued2022-01-01
dc.description.abstract© 2022 Marmara University Press.The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients.
dc.identifier.citationOKUYAN B., TOK F., KARAKUŞ S., Dalgiç N., ÇAKIR E., Midyat L., Koçyiğit-Kaymakçioğlu B., Berk U. E. , İZZETTİN F. V. , Rollas S., et al., "Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography", Journal of Research in Pharmacy, cilt.26, sa.6, ss.1907-1914, 2022
dc.identifier.doi10.29228/jrp.281
dc.identifier.endpage1914
dc.identifier.issn2630-6344
dc.identifier.issue6
dc.identifier.startpage1907
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85142171688&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/284219
dc.identifier.volume26
dc.language.isoeng
dc.relation.ispartofJournal of Research in Pharmacy
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectLife Sciences (LIFE)
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectHPLC
dc.subjectpediatric patients
dc.subjecttherapeutic drug monitoring
dc.subjecttuberculosis
dc.titleTherapeutic drug monitoring in pediatric patients treated with anti-tuberculosis medications by high performance liquid chromatography
dc.typearticle
dspace.entity.typePublication
local.avesis.idb5a24bc4-745b-42dc-abad-b0e804a3586e
local.indexed.atSCOPUS
relation.isAuthorOfPublicationf6e7969a-ea61-403f-8772-1a8478556223
relation.isAuthorOfPublication0a1c1aab-25cc-4eb2-9121-496da16c3ff1
relation.isAuthorOfPublicationc93b8083-3f67-4147-bd81-8587eaba18ad
relation.isAuthorOfPublication0f8e7ba6-02e7-4232-84bb-31777a356761
relation.isAuthorOfPublication87a6fc65-406c-478f-bc6d-ffaaaf1f7b31
relation.isAuthorOfPublication.latestForDiscoveryf6e7969a-ea61-403f-8772-1a8478556223

Files

Collections

Research Outputs